Australia Alexipharmic Drugs Market Report 2022 to 2030

Australia Alexipharmic Drugs Market Analysis

$ 3999

Australia's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 6.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The rising incidence of poisonings due to accidental or intentional exposure to toxins is driving the demand for alexipharmic drugs in Australia. The key market players are CSL Behring, Hospira, Mylan, Phebra (AUS), and others.

ID: IN10AUPH004 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Chandani Patel

Buy Now

Australia Alexipharmic Drugs Market Executive Summary

The Australia Alexipharmic Drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.20% from 2022 to 2030 and will reach $xx Bn in 2030. As of 2021, Australia's total healthcare expenditure is estimated to be approximately AUD 200 billion, with an average annual growth rate of 4.2% over the past decade. This expenditure is funded through a mix of private and public sources, with the Australian Government being the largest funder of healthcare in the country. The pharmaceutical market is dominated by both domestic and international pharmaceutical companies.

Alexipharmic drugs, also known as antidotes, are medications used to treat poisoning or toxic overdose. In Australia, several alexipharmic drugs are available and can be obtained with a prescription from a doctor or hospital. The availability of these drugs may vary depending on the location and the type of poisoning being treated. In some cases, they may only be available in hospitals or specialized poison control centers.

The primary factors influencing the growth of the demand for alexipharmic drugs have also been established with potential gravity. The increase in the prevalence of various types of chronic diseases and overdose of prescribed drugs drives the Alexipharmic drugs market in Australia.

Market Dynamics

Market Growth Drivers

The rising incidence of poisonings due to accidental or intentional exposure to toxins is driving the demand for alexipharmic drugs in Australia.

Growing awareness of the availability of antidotes: The increasing awareness among healthcare professionals and the general public about the availability and use of alexipharmic drugs is also driving the market
Government initiatives: The Australian government has implemented various initiatives aimed at promoting the availability and use of antidotes, which is also contributing to the growth of the market

Market Restraints

High cost: The cost of alexipharmic drugs can be high, which may limit access for some patients
Limited availability: Certain antidotes may be limited in availability, especially in rural or remote areas, which can restrict access to treatment
Safety concerns: Some alexipharmic drugs have the potential for serious adverse effects, which can limit their use in some patients

Competitive Landscape

Key Players

CSL Behring
Hospira
Mylan
Phebra (AUS)
Pfizer Inc.
Bausch Health Companies Inc
Mylan N.V.
Merck & Co., Inc.
GlaxoSmithKline plc.
Sanofi
Roche Holding AG
Novartis International AG
Bayer AG

Notable Deals

Merck's acquisition of Antelliq: In 2019, Merck completed its acquisition of Antelliq, a company that produces a range of animal health products, including antidotes for toxic exposure in livestock. The deal was valued at approximately $3.47 Bn.

Healthcare Policies and Regulatory Landscape

The Therapeutic Goods Administration (TGA) is the regulatory authority responsible for the evaluation, approval, and post-market surveillance of therapeutic goods, including alexipharmic drugs, in Australia. To be approved for use, these drugs must meet the TGA's standards for safety, quality, and efficacy.

The Australian government subsidizes the cost of many prescription medications through the Pharmaceutical Benefits Scheme (PBS). Alexipharmic drugs may be listed on the PBS if they are deemed to be cost-effective and have been approved by the TGA. This means that eligible patients can receive these drugs at a reduced cost, or in some cases, free of charge.

In addition, the Australian government also provides funding for the National Poison Centre Network, which provides expert advice on the management of poisonings, including the use of antidotes.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alexipharmic Drugs Market Segmentation

By Product Type (Revenue, USD Billion):

The product type segment contributed the largest share to the Alexipharmic Drugs Market in 2021; this segment is projected to grow at the highest CAGR from 2022 to 2030.

Tetraethylthiuram Disulfide
Glutathione
EDTA
Penicillamine
Methylene Blue
Diethylenetriaminepentaacetic Acid
2 Aminoethanethiol
Sodium Nitrite
Dimercapto Propanol
Triethylenetetramine
Na-DMS
Naloxone
Naltrexone
Sodium Thiosulfate
Pyraloxime
Pralidoxime Iodide
Flumazenil

By Indication (Revenue, USD Billion):

Alcoholic Overdose
Opioid Overdose
Cyanide Poisoning
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By End User (Revenue, USD Billion):

Hospitals
Specialty Clinics
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.